Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

Toshiaki Okada, Nagio Takigawa, Daizo Kishino, Hideki Katayama, Shouichi Kuyama, Ken Sato, Junko Mimoto, Hiroshi Ueoka, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

Abstract

Cisplatin is used to treat lung cancer; however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups: group 1, no treatment; group 2, low-dose celecoxib (150 mg/kg); group 3, high-dose celecoxib (1,500 mg/kg); group 4, cisplatin alone; group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62 mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p <0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p <0.01, group 4 vs. group 6).

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalActa Medica Okayama
Volume66
Issue number3
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase 2 Inhibitors
Cisplatin
Carcinogenesis
Tumors
Neoplasms
Carcinogens
Cyclooxygenase 2
Lung Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. / Okada, Toshiaki; Takigawa, Nagio; Kishino, Daizo; Katayama, Hideki; Kuyama, Shouichi; Sato, Ken; Mimoto, Junko; Ueoka, Hiroshi; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Acta Medica Okayama, Vol. 66, No. 3, 06.2012, p. 245-251.

Research output: Contribution to journalArticle

Okada, T, Takigawa, N, Kishino, D, Katayama, H, Kuyama, S, Sato, K, Mimoto, J, Ueoka, H, Tanimoto, M & Kiura, K 2012, 'Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.', Acta Medica Okayama, vol. 66, no. 3, pp. 245-251.
Okada T, Takigawa N, Kishino D, Katayama H, Kuyama S, Sato K et al. Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. Acta Medica Okayama. 2012 Jun;66(3):245-251.
Okada, Toshiaki ; Takigawa, Nagio ; Kishino, Daizo ; Katayama, Hideki ; Kuyama, Shouichi ; Sato, Ken ; Mimoto, Junko ; Ueoka, Hiroshi ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. In: Acta Medica Okayama. 2012 ; Vol. 66, No. 3. pp. 245-251.
@article{0872ad18a1f84de289cc91c2c6066bf8,
title = "Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.",
abstract = "Cisplatin is used to treat lung cancer; however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups: group 1, no treatment; group 2, low-dose celecoxib (150 mg/kg); group 3, high-dose celecoxib (1,500 mg/kg); group 4, cisplatin alone; group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62 mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8{\%} in group 1, 25{\%} in group 2, 26.3{\%} in group 3, 60{\%} in group 4, 50{\%} in group 5, and 50{\%} in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p <0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p <0.01, group 4 vs. group 6).",
author = "Toshiaki Okada and Nagio Takigawa and Daizo Kishino and Hideki Katayama and Shouichi Kuyama and Ken Sato and Junko Mimoto and Hiroshi Ueoka and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2012",
month = "6",
language = "English",
volume = "66",
pages = "245--251",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

AU - Okada, Toshiaki

AU - Takigawa, Nagio

AU - Kishino, Daizo

AU - Katayama, Hideki

AU - Kuyama, Shouichi

AU - Sato, Ken

AU - Mimoto, Junko

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2012/6

Y1 - 2012/6

N2 - Cisplatin is used to treat lung cancer; however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups: group 1, no treatment; group 2, low-dose celecoxib (150 mg/kg); group 3, high-dose celecoxib (1,500 mg/kg); group 4, cisplatin alone; group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62 mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p <0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p <0.01, group 4 vs. group 6).

AB - Cisplatin is used to treat lung cancer; however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups: group 1, no treatment; group 2, low-dose celecoxib (150 mg/kg); group 3, high-dose celecoxib (1,500 mg/kg); group 4, cisplatin alone; group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62 mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p <0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p <0.01, group 4 vs. group 6).

UR - http://www.scopus.com/inward/record.url?scp=84867904777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867904777&partnerID=8YFLogxK

M3 - Article

C2 - 22729105

VL - 66

SP - 245

EP - 251

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -